256 related articles for article (PubMed ID: 21812510)
1. Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy.
Judge DP; Kass DA; Thompson WR; Wagner KR
Am J Cardiovasc Drugs; 2011 Oct; 11(5):287-94. PubMed ID: 21812510
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy.
Ogata H; Ishikawa Y; Ishikawa Y; Minami R
J Cardiol; 2009 Feb; 53(1):72-8. PubMed ID: 19167641
[TBL] [Abstract][Full Text] [Related]
3. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy.
Jefferies JL; Eidem BW; Belmont JW; Craigen WJ; Ware SM; Fernbach SD; Neish SR; Smith EO; Towbin JA
Circulation; 2005 Nov; 112(18):2799-804. PubMed ID: 16246949
[TBL] [Abstract][Full Text] [Related]
4. Cardiac and respiratory dysfunction in Duchenne muscular dystrophy and the role of second messengers.
Mosqueira M; Zeiger U; Förderer M; Brinkmeier H; Fink RH
Med Res Rev; 2013 Sep; 33(5):1174-213. PubMed ID: 23633235
[TBL] [Abstract][Full Text] [Related]
5. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy.
Viollet L; Thrush PT; Flanigan KM; Mendell JR; Allen HD
Am J Cardiol; 2012 Jul; 110(1):98-102. PubMed ID: 22463839
[TBL] [Abstract][Full Text] [Related]
6. Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy.
Su JB; Cazorla O; Blot S; Blanchard-Gutton N; Ait Mou Y; Barthélémy I; Sambin L; Sampedrano CC; Gouni V; Unterfinger Y; Aguilar P; Thibaud JL; Bizé A; Pouchelon JL; Dabiré H; Ghaleh B; Berdeaux A; Chetboul V; Lacampagne A; Hittinger L
Cardiovasc Res; 2012 Jul; 95(1):86-96. PubMed ID: 22562664
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibitors and beta-blockers in cardiac asymptomatic patients with Duchenne muscular dystrophy.
Fayssoil A
Indian Heart J; 2010; 62(3):273. PubMed ID: 21275309
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies.
Mavrogeni SI; Markousis-Mavrogenis G; Papavasiliou A; Papadopoulos G; Kolovou G
Methods Mol Biol; 2018; 1687():31-42. PubMed ID: 29067654
[TBL] [Abstract][Full Text] [Related]
9. [Effective milrinone therapy to a Duchenne muscular dystrophy patient with advanced congestive heart failure].
Matsumura T; Saito T; Miyai I; Nozaki S; Kang J
Rinsho Shinkeigaku; 1999 Jun; 39(6):643-8. PubMed ID: 10502990
[TBL] [Abstract][Full Text] [Related]
10. [Management of myocardial damage in muscular dystrophy].
Tamura T
Brain Nerve; 2011 Nov; 63(11):1217-28. PubMed ID: 22068474
[TBL] [Abstract][Full Text] [Related]
11. Left Ventricular Tonic Contraction as a Novel Biomarker of Cardiomyopathy in Duchenne Muscular Dystrophy.
Su JA; Ramos-Platt L; Menteer J
Pediatr Cardiol; 2016 Apr; 37(4):678-85. PubMed ID: 26714815
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological therapy for the prevention and management of cardiomyopathy in Duchenne muscular dystrophy: A systematic review.
El-Aloul B; Altamirano-Diaz L; Zapata-Aldana E; Rodrigues R; Malvankar-Mehta MS; Nguyen CT; Campbell C
Neuromuscul Disord; 2017 Jan; 27(1):4-14. PubMed ID: 27815032
[TBL] [Abstract][Full Text] [Related]
13. Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life.
Ramaciotti C; Heistein LC; Coursey M; Lemler MS; Eapen RS; Iannaccone ST; Scott WA
Am J Cardiol; 2006 Sep; 98(6):825-7. PubMed ID: 16950195
[TBL] [Abstract][Full Text] [Related]
14. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
Dittrich S; Graf E; Trollmann R; Neudorf U; Schara U; Heilmann A; von der Hagen M; Stiller B; Kirschner J; Pozza RD; Müller-Felber W; Weiss K; von Au K; Khalil M; Motz R; Korenke C; Lange M; Wilichowski E; Pattathu J; Ebinger F; Wiechmann N; Schröder R;
Orphanet J Rare Dis; 2019 May; 14(1):105. PubMed ID: 31077250
[TBL] [Abstract][Full Text] [Related]
15. Cardiomyopathy of Duchenne muscular dystrophy: pathogenesis and prospect of membrane sealants as a new therapeutic approach.
Townsend D; Yasuda S; Metzger J
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):99-109. PubMed ID: 17187461
[TBL] [Abstract][Full Text] [Related]
16. Electrocardiographic findings in mdx mice: a cardiac phenotype of Duchenne muscular dystrophy.
Chu V; Otero JM; Lopez O; Sullivan MF; Morgan JP; Amende I; Hampton TG
Muscle Nerve; 2002 Oct; 26(4):513-9. PubMed ID: 12362417
[TBL] [Abstract][Full Text] [Related]
17. Occult cardiac contractile dysfunction in dystrophin-deficient children revealed by cardiac magnetic resonance strain imaging.
Ashford MW; Liu W; Lin SJ; Abraszewski P; Caruthers SD; Connolly AM; Yu X; Wickline SA
Circulation; 2005 Oct; 112(16):2462-7. PubMed ID: 16216964
[TBL] [Abstract][Full Text] [Related]
18. Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy.
Schade van Westrum SM; Hoogerwaard EM; Dekker L; Standaar TS; Bakker E; Ippel PF; Oosterwijk JC; Majoor-Krakauer DF; van Essen AJ; Leschot NJ; Wilde AA; de Haan RJ; de Visser M; van der Kooi AJ
Neurology; 2011 Jul; 77(1):62-6. PubMed ID: 21700587
[TBL] [Abstract][Full Text] [Related]
19. [Association between dystrophin and neuronal nitric oxide synthase in muscles of progressive muscular dystrophy].
Wang S; Shen D
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):155-7. PubMed ID: 11953148
[TBL] [Abstract][Full Text] [Related]
20. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy.
Duboc D; Meune C; Lerebours G; Devaux JY; Vaksmann G; Bécane HM
J Am Coll Cardiol; 2005 Mar; 45(6):855-7. PubMed ID: 15766818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
